HK1041817A1 - Drug combinations comprising (e)-7-Ä4-(4-fluorophenyl)-6-isopropyl-2-Ämethyl(methylsulfonyl)aminoÜpyrimidin-5-ylÜ(3r, 5s)-3,5-dihydroxyhept-6-enoic acid and an inhibitor, inducer or substrate of p450 isoenzyme 3a4. - Google Patents

Drug combinations comprising (e)-7-Ä4-(4-fluorophenyl)-6-isopropyl-2-Ämethyl(methylsulfonyl)aminoÜpyrimidin-5-ylÜ(3r, 5s)-3,5-dihydroxyhept-6-enoic acid and an inhibitor, inducer or substrate of p450 isoenzyme 3a4.

Info

Publication number
HK1041817A1
HK1041817A1 HK02103512A HK02103512A HK1041817A1 HK 1041817 A1 HK1041817 A1 HK 1041817A1 HK 02103512 A HK02103512 A HK 02103512A HK 02103512 A HK02103512 A HK 02103512A HK 1041817 A1 HK1041817 A1 HK 1041817A1
Authority
HK
Hong Kong
Prior art keywords
ämethyl
ylü
aminoüpyrimidin
dihydroxyhept
isoenzyme
Prior art date
Application number
HK02103512A
Other languages
English (en)
Inventor
Ali Raza
John Stuart Pears
Howard Gerard Hutchinson
Dennis Schneck
Takahiko Baba
Akira Touchi
Yoshitaka Yamaguchi
Original Assignee
Astrazeneca Ab
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27269637&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1041817(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9902593.4A external-priority patent/GB9902593D0/en
Priority claimed from GBGB9921064.3A external-priority patent/GB9921064D0/en
Priority claimed from GBGB9921063.5A external-priority patent/GB9921063D0/en
Application filed by Astrazeneca Ab, Shionogi & Co filed Critical Astrazeneca Ab
Publication of HK1041817A1 publication Critical patent/HK1041817A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
HK02103512A 1999-02-06 2002-05-08 Drug combinations comprising (e)-7-Ä4-(4-fluorophenyl)-6-isopropyl-2-Ämethyl(methylsulfonyl)aminoÜpyrimidin-5-ylÜ(3r, 5s)-3,5-dihydroxyhept-6-enoic acid and an inhibitor, inducer or substrate of p450 isoenzyme 3a4. HK1041817A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9902593.4A GB9902593D0 (en) 1999-02-06 1999-02-06 Drug combinations
GBGB9921064.3A GB9921064D0 (en) 1999-09-08 1999-09-08 Drug combination
GBGB9921063.5A GB9921063D0 (en) 1999-09-08 1999-09-08 Therapy
PCT/GB2000/000278 WO2000045817A1 (en) 1999-02-06 2000-02-01 Drug combinations comprising (e) -7 - [4 -(4 -fluorophenyl) -6 - isopropyl -2 - [methyl (methylsulfonyl) amino] pyrimidin -5 -yl] (3r,5s) -3,5 - dihydroxyhept -6 - enoic acid and an inhibitor, inducer or substrate of p450 isoenzyme 3a4

Publications (1)

Publication Number Publication Date
HK1041817A1 true HK1041817A1 (en) 2002-07-26

Family

ID=27269637

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02103512A HK1041817A1 (en) 1999-02-06 2002-05-08 Drug combinations comprising (e)-7-Ä4-(4-fluorophenyl)-6-isopropyl-2-Ämethyl(methylsulfonyl)aminoÜpyrimidin-5-ylÜ(3r, 5s)-3,5-dihydroxyhept-6-enoic acid and an inhibitor, inducer or substrate of p450 isoenzyme 3a4.

Country Status (29)

Country Link
US (3) US6982157B1 (ja)
EP (1) EP1185274B1 (ja)
JP (2) JP2002536331A (ja)
KR (2) KR20060117381A (ja)
CN (1) CN1165310C (ja)
AR (1) AR029333A1 (ja)
AT (1) ATE282415T1 (ja)
AU (1) AU767304B2 (ja)
BR (1) BR0007999A (ja)
CA (1) CA2358632C (ja)
CZ (1) CZ301296B6 (ja)
DE (1) DE60015965T2 (ja)
EE (1) EE04929B1 (ja)
EG (1) EG23858A (ja)
ES (1) ES2232418T3 (ja)
GB (1) GB0000710D0 (ja)
HK (1) HK1041817A1 (ja)
ID (1) ID30485A (ja)
IL (1) IL144715A0 (ja)
IS (1) IS2337B (ja)
MX (1) MXPA01007905A (ja)
MY (1) MY130606A (ja)
NO (1) NO320745B1 (ja)
NZ (1) NZ512982A (ja)
PL (1) PL198034B1 (ja)
PT (1) PT1185274E (ja)
TR (1) TR200102228T2 (ja)
TW (1) TWI282738B (ja)
WO (1) WO2000045817A1 (ja)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
DE19944803A1 (de) * 1999-09-20 2001-03-29 Bayer Ag Kombination von Dihydropyridinverbindungen und HMG-CoA-Reduktase-Inhibitoren und ihre Verwendung in Arzneimitteln
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
GB0003305D0 (en) 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
US9173847B2 (en) 2003-10-10 2015-11-03 Veloxis Pharmaceuticals A/S Tablet comprising a fibrate
EP1680091B1 (en) 2003-10-10 2017-05-31 Veloxis Pharmaceuticals A/S A solid dosage form comprising a fibrate
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US7642287B2 (en) 2004-08-06 2010-01-05 Transform Pharmaceuticals, Inc. Statin pharmaceutical compositions and related methods of treatment
EP1948600B1 (en) 2005-07-05 2014-04-16 The President & Fellows Of Harvard College Liver targeted conjugates
CN101330919B (zh) * 2005-12-20 2012-12-05 力奇制药公司 包含(e)-7-[4-(4-氟苯基)-6-异丙基-2-[甲基(甲磺酰基)氨基]嘧啶-5-基]-(3r,5s)-3,5-二羟基庚-6-烯酸的药物组合物
US20080109252A1 (en) * 2006-11-08 2008-05-08 Lafountain Andrea Predicting patient compliance with medical treatment
US20120130202A1 (en) * 2010-11-24 2012-05-24 Fujitsu Limited Diagnosis and Monitoring of Musculoskeletal Pathologies
AU2019285170A1 (en) * 2018-06-14 2021-01-28 Astrazeneca Uk Limited Methods for lowering blood pressure with a dihydropyridine-type calcium channel blocker pharmaceutical composition
RS63740B1 (sr) 2019-07-31 2022-12-30 Intas Pharmaceuticals Ltd Farmaceutski sastav koji se sastoji od inhibitora hmg-coa reduktaze i fenofibrata

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2627696B1 (fr) * 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
DE59200802D1 (de) * 1991-07-02 1995-01-05 Benckiser Gmbh Joh A Zusammenfaltbare Vorratsflasche.
JP3852621B2 (ja) * 1992-01-21 2006-12-06 あすか製薬株式会社 血管内皮細胞機能改善剤
FR2730231B1 (fr) * 1995-02-02 1997-04-04 Fournier Sca Lab Association de fenofibrate et de vitamine e, utilisation en therapeutique
JP4738592B2 (ja) * 1997-10-31 2011-08-03 アーチ・デヴェロップメント・コーポレイション ５α−還元酵素活性を調節するための方法及び組成物

Also Published As

Publication number Publication date
MXPA01007905A (es) 2003-06-04
CA2358632C (en) 2008-10-28
AR029333A1 (es) 2003-06-25
EP1185274B1 (en) 2004-11-17
NO20013811L (no) 2001-10-02
US6982157B1 (en) 2006-01-03
MY130606A (en) 2007-07-31
KR20060117381A (ko) 2006-11-16
CA2358632A1 (en) 2000-08-10
US20060040969A1 (en) 2006-02-23
NO320745B1 (no) 2006-01-23
IL144715A0 (en) 2002-06-30
ATE282415T1 (de) 2004-12-15
CZ20012844A3 (cs) 2001-11-14
PT1185274E (pt) 2005-03-31
JP2002536331A (ja) 2002-10-29
WO2000045817A1 (en) 2000-08-10
JP2007277267A (ja) 2007-10-25
GB0000710D0 (en) 2000-03-08
IS6009A (is) 2001-07-17
CN1338936A (zh) 2002-03-06
NO20013811D0 (no) 2001-08-03
AU2121800A (en) 2000-08-25
TR200102228T2 (tr) 2002-03-21
IS2337B (is) 2008-02-15
KR20010101790A (ko) 2001-11-14
PL364780A1 (en) 2004-12-13
AU767304B2 (en) 2003-11-06
ES2232418T3 (es) 2005-06-01
EG23858A (en) 2007-11-18
US20090042911A1 (en) 2009-02-12
PL198034B1 (pl) 2008-05-30
EE200100406A (et) 2002-10-15
EP1185274A1 (en) 2002-03-13
ID30485A (id) 2001-12-13
BR0007999A (pt) 2001-11-06
NZ512982A (en) 2003-08-29
DE60015965T2 (de) 2006-01-05
CN1165310C (zh) 2004-09-08
CZ301296B6 (cs) 2010-01-06
TWI282738B (en) 2007-06-21
EE04929B1 (et) 2007-12-17
DE60015965D1 (de) 2004-12-23

Similar Documents

Publication Publication Date Title
HK1041817A1 (en) Drug combinations comprising (e)-7-Ä4-(4-fluorophenyl)-6-isopropyl-2-Ämethyl(methylsulfonyl)aminoÜpyrimidin-5-ylÜ(3r, 5s)-3,5-dihydroxyhept-6-enoic acid and an inhibitor, inducer or substrate of p450 isoenzyme 3a4.
DE60045168D1 (de) Kombinationspräparate enthaltend (E)-7-Ä4-(4-fluorophenyl)-6-isopropyl-2-Ämethyl(methylsulfonyl)aminoÜpyrimidin-5-ylÜ(3r,5s)-3,5-dihydroxyhept-6-enoic Säure
TR200103216T2 (tr) Pirimidinon bileşimleri
BR9908280A (pt) Inibidores de enzimas de fosfolipase
AP2004003189A0 (en) Use of CETP inhibitors and optionally HMG COA reductase inhibitors and/or antihypertensive agents.
MXPA03007049A (es) Inhibidores heterociclicos de erk2 y usos de los mismos.
WO2004037176A3 (en) Quinazolinones and derivatives thereof as factor xa inhibitors
WO2004112482A8 (en) Biological active coating components, coatings, and coated surfaces
DZ3170A1 (fr) Livraison de produits pharmaceutiques instables.
AU2002258997A1 (en) Polymerases with charge-switch activity and methods of generating such polymerases
AU2003224371A1 (en) Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same
AU2003239544A1 (en) Amplification and overexpression of oncogenes
WO2004027056A3 (en) Methods of use for thermostable rna ligases
AU762955C (en) Methods and compositions useful for modulation of angiogenesis using tyrosine kinase SRC
AU2002341799A1 (en) Identifying drugs for and diagnosis of benign prostatic hyperplasia using gene expression profiles
AU2003254064A1 (en) Amplification and overexpression of oncogenes
AU2002359403A1 (en) METHODS AND COMPOSITIONS FOR REGULATION OF GENE EXPRESSION THROUGH MODULATION OF mRNA TURNOVER
SI1185274T1 (en) Drug combinations comprising (e)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(methyl(methylsulfonyl)amino)pyrimidin-5-yl)(3r,5s)-3,5-dihydroxyhept-6-enoic acid and an inhibitor, inducer or substrate of p450 isoenzyme 3a4
HUP0104977A3 (en) Drug combinations comprising (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl-(methylsulfonyl)-amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid and an inhibitor, inducer or substrate of p450 isoenzyme 3a4
AU5530800A (en) Method and composition for enhancing the activity of an enzyme
DK1185274T3 (da) Lægemiddelkombinationer omfattende (E) - 7 -[4- (4-fluorphenyl) - 6 - isopropyl-2 [methyl(methylsulfonyl)amino ]-pyrimidin-5-yl] (3R,5S) - 3,5-dihydroxyhept-6-ensyre og en inhibitor af, en inducer af eller et substrat for P450 isoenzym 3A4
AU2002336967A1 (en) 2, 5-substituted 1-(aminocarbonylalkyl) -pyrimidin-4-one derivatives with lp-pla2 inhinitory activity for the treatment of atherosclerosis
AU1270801A (en) Phosphostannate or borostannate pyrolitic coating, and glazing comprising same
AU2002318429A1 (en) Usp-3like deubiquitinating enzyme gene disruptions, compositions and methods related thereto
AU1386501A (en) Method and composition for enhancing the activity of an enzyme